Update on the emerging role of telavancin in hospital-acquired infections

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 605-610

  Nnedu, Obinna N ^a   Pankey, George A ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Linezolid; Staphylococcus aureus; Telavancin; Vancomycin

Indexed keywords

TELAVANCIN;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BACTERICIDAL ACTIVITY; CATHETER INFECTION; CONSTIPATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HOSPITAL INFECTION; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INSOMNIA; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INFECTION; TASTE DISORDER; URINARY TRACT INFECTION;

EID: 84928159111     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S57376     Document Type: Article

References (38)

1. Types of Healthcare-associated Infections [page on the Internet]. Atlanta: Centers for Disease Control and Prevention; c2014 [updated March 26, 2014; cited December 1, 2014]. Available from: http://www.cdc.gov/ HAI/infectionTypes.html. Accessed February 9, 2015.
2. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58(2):338–343.
3. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomy-cin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58(6):1177–1184.
4. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(7):2647–2652.
5. Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavan-cin against grampositive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother. 2007;51(9):3420–3424.
6. Pankey gA, Ashcraft DS. In vitro synergy of telavancin and rifampin against Enterococcus faecium resistant to both linezolid and vancomy-cin. Ochsner J. 2013;13(1):61–65.
7. Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of gram-positive clinical pathogens from fve continents. Antimicrob Agents Chemother. 2012;56(7):3999–4004.
8. Farrell DJ, Mendes RE, Rhomberg PR, Jones RN. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother. 2014;58(9):5547–5551.
9. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in US hospitals (2011–2012) as determined by the revised susceptibility testing method. Antimicrob Agents Chemother. 2015;59(1):702–706.
10. goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopep-tide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004;48(6): 2149–2152.
11. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(3):1127–1134.
12. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother. 2004;48(8):3043–3050.
13. Shaw JP, Seroogy J, Kaninga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):195–201.
14. Plotkin P, Patel K, Uminski A, Marzella N. Telavancin (vibativ), a new option for the treatment of gram-positive infections. P T. 2011;36(3): 127–138.
15. Rubinstein E, Lalani T, Corey gR, et al. Telavancin vs vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52(1):31–40.
16. Rubinstein E, Stryjewski ME, Barrierre SL. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. Infect Drug Resist. 2014;7:129–135.
17. Stryjewski ME, Barrierre SL, Rubinstein E, et al. Telavancin vs vancomycin for bacteraemic hospitalized-acquired pneumonia. Int J Antimicrob Agents. 2013;42(4):367–369.
18. Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11): 1601–1607.
19. Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862–867.
20. Stryjewski ME, graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683–1693.
21. Wilson SE, O’Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM; ATLAS investigators. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg. 2009;197(6):791–796.
22. VIBATIV [package insert]. South San Francisco, CA: Theravance, Inc.; 2013. Available from: www.vibativ.com. Accessed August 7, 2014.
23. Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014;80(4):327–329.
24. Barriere SL. ATLAS trials: effcacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010;5(12):1765–1773.
25. LaPlante KL, Mermel LA. In vitro activities of telavancin and vanco-mycin against bioflmproducing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother. 2009;53(7):3166–3169.
26. Smith K, gemmell Cg, Lang S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro bioflm models. Eur J Clin Microbiol Infect Dis. 2013;32(10): 1327–1332.
27. gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a bioflm model. J Antimicrob Chemother. 2005;56(2): 337–343.
28. Kaushal R, Hassoun A. Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin. J Antimicrob Chemother. 2012;67(8):2052–2053.
29. Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289.
30. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphy-lococcus aureus endocarditis with telavancin. J Antimicrob Chemother. 2010;65(6):1315–1316.
31. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with tela-vancin. Antimicrob Agents Chemother. 2010;54(12):5376–5378.
32. Joson J, grover C, Downer C, Pujar T, Heidari A. Successful treatment of methicillinresistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following dap-tomycin failure. J Antimicrob Chemother. 2011;66(9):2186–2188.
33. Chaftari A, Hachem R, Jordan M, et al. Evaluation of telavancin in the treatment of grampositive bloodstream infections in cancer patients. Poster presented at: IDWeek; October 8–12, 2014; Philadelphia, PA.
34. Corey gR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. Epub December 3, 2014. pii: ciu971.
35. Kenyan Y, Rubinstein E. Telavancin in the treatment of invasive gram-positive infections. Clin Audit. 2012;4:25–29.
36. Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME. Effcacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7(8):e41870.
37. Corey gR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014;58(4):2030–2037.
38. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008;28(12):1471–1482.